Lipopolysaccharide antagonists

Immunol Today. 1992 Jul;13(7):271-6. doi: 10.1016/0167-5699(92)90009-V.

Abstract

Bacterial lipopolysaccharide (LPS) is a potent and pleiotropic stimulus of immune cells. LPS has important clinical relevance because it has a direct role in the pathogenesis of Gram-negative bacterial infection. The lipid A moiety of LPS is responsible for the toxic effects of LPS. The identification of structural analogs and precursors of lipid A, which are apparently competitive antagonists of the biological actions of LPS, is strong evidence that the actions of LPS are mediated by a specific LPS receptor or family of receptors. Identification and analysis of these LPS receptors with LPS antagonists should help to define the pathways of cellular activation by LPS and lead to the development of novel anti-LPS strategies in the therapy of bacterial diseases.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.
  • Review

MeSH terms

  • Antimicrobial Cationic Peptides
  • Blood Proteins / pharmacology
  • Cytokines / metabolism
  • Endotoxins / antagonists & inhibitors*
  • Gram-Negative Bacterial Infections / drug therapy
  • Gram-Negative Bacterial Infections / immunology
  • Gram-Negative Bacterial Infections / physiopathology
  • Humans
  • Lipid A / analogs & derivatives
  • Lipid A / antagonists & inhibitors
  • Lipid A / chemistry
  • Lipopolysaccharides / physiology*
  • Lipopolysaccharides / toxicity
  • Lymphocyte Activation
  • Membrane Proteins*
  • Polymyxin B / pharmacology*
  • Polymyxin B / therapeutic use
  • Receptors, Immunologic / drug effects

Substances

  • Antimicrobial Cationic Peptides
  • Blood Proteins
  • Cytokines
  • Endotoxins
  • Lipid A
  • Lipopolysaccharides
  • Membrane Proteins
  • Receptors, Immunologic
  • bactericidal permeability increasing protein
  • endotoxin receptor
  • Polymyxin B